Thornton and colleagues examined the effects of two NLRP3 inflammasome inhibitors (NT-0249 and NT-0796) on obesity-induced complications such as systemic inflammation and astrogliosis. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.